Stock comparison
LeMaitre Vascular
West Pharmaceutical Services
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
WST
West Pharmaceutical Services
Market cap
$21.21B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | WST | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 55C | LMAT |
| Benjamin Graham | 81A | 80A | LMAT |
| Philip Fisher | 73B | 39D | LMAT |
| Peter Lynch | 59C | 16F | LMAT |
| Joel Greenblatt | 48D | 52C | WST |
| Charlie Munger | 60C | 52C | LMAT |
| Terry Smith | 61C | 46D | LMAT |
Side-by-side metrics
| Metric | LMAT | WST |
|---|---|---|
| Market cap | $2.32B | $21.21B |
| P/E (TTM) | 37.1x | 39.8x |
| EV/EBIT | 36.6x | 34.0x |
| ROIC (TTM) | 9.43% | 15.24% |
| Gross margin | 72.39% | 36.24% |
| Net margin | 24.35% | 16.85% |
| Revenue CAGR 5y | 12.75% | 2.08% |
| EPS CAGR 5y | 19.04% | -6.4% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.29% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -6.4%+134%
- Revenue CAGR 5y12.75%vs 2.08%+84%
- Dividend yield0.84%vs 0.29%+65%
- Gross margin72.39%vs 36.24%+50%
WST leads on
- Market cap$21.21Bvs $2.32B+89%
- Debt / Equity0.1xvs 0.5x+77%
- ROIC (TTM)15.24%vs 9.43%+38%
- EV/EBIT34.0xvs 36.6x+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.